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Purpose: To report on the efficacy of selective laser trabeculoplasty (SLT) for elevated 
  intraocular pressure (IOP) following subtenon injection of triamcinolone acetonide.
Method: SLT was performed on four of 148 eyes in which IOP was elevated after a subtenon 
injection of triamcinolone acetonide and could not be maintained within normal limits by 
  conventional medications. Postoperative IOP and relative reduction of IOP were evaluated.
Results: IOP was reduced in three eyes to within the normal range without any medications six 
months after SLT alone, but trabeculotomy was performed on one eye. Percentage reduction in 
IOP after SLT was 21.6% at one month, 45.0% at three months, and 52.7% at nine months.
Conclusion: SLT may be effective in reducing elevated IOP following subtenon injection of 
triamcinolone acetonide and should be considered before glaucoma surgery.
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Introduction
One complication of intravitreal or subtenon injection of triamcinolone acetonide 
(SITA) is an elevation of intraocular pressure (IOP).1 Argon laser trabeculoplasty and 
selective laser trabeculoplasty (SLT) have been used to treat elevated IOP following 
intravitreal injection of triamcinolone acetonide (IVTA).2,3 However, the elevation of 
the IOP after SITA is different from that following IVTA because a higher dose is 
injected which may have a long-lasting effect.4 The effectiveness of SLT following 
SITA has not been examined. Thus, we have investigated whether SLT is effective 
in reducing elevated IOP after SITA.
Methods
SITA of 10 or 20 mg was performed on 148 eyes between 2004 and 2006 at the Keio 
University Hospital. Written informed consent was obtained from all patients before 
SITA. Institutional approval was obtained for this retrospective clinical review. All 
patients were followed for at least nine months.
IOP was measured before and after SITA by Goldmann applanation tonometry. 
SLT was performed when IOP had increased to 26 mmHg with intensive medica-
tions, including topical ocular medications and oral acetazolamide. Postoperative IOP 
and relative reduction of IOP were evaluated.
A Nd:YAG half-wave Q switch laser (SELECTA duet, Japan Lumenis, Tokyo) 
was used for the SLT at a wavelength at 532 nm, spot size 400 µm, and exposure 
time of 3 nsec. Forty spots were applied to the inferior 180° sector with an energy of Clinical Ophthalmology 2010:4 248
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0.8 to 1.0 mJ, and small gas bubbles were observed after each 
shot. The preoperative topical and systemic medications were 
continued postoperatively. Topical hydrochloric apraclonidine 
was applied 30 minutes before and immediately after the SLT 
procedure. Anti-inflammatory medications, such as steroid eye 
drops, were not used.
Results
SITA of 10 or 20 mg was performed for retinal vein occlu-
sion, choroidal neovascularization, or diabetic maculopathy 
before anti-vascular endothelial growth factor therapy was 
introduced. IOP increased to 21 mmHg in 44 (30%) of 
148 eyes after SITA, and anti-glaucoma medications were 
used. SLT was performed in four eyes of four patients (one 
man and three women, mean age 37.5 ± 7.3 years) from two 
to three months after SITA when the IOP had not decreased 
after the use of anti-glaucoma medications. In the other 
144 eyes, the IOP gradually decreased to baseline IOP in 
10 months, with a reduction in the number of anti-glaucoma 
medications. The IOP before SITA in the four eyes in which 
SLT was performed ranged between 14 and 19 mmHg. The 
angle was classified as Shaffer 3 by gonioscopy. There was no 
evidence of angle neovascularization before SITA and SLT 
treatment (Table 1). The presence of glaucomatous disc cup-
ping5,6 which was defined as a vertical cup-to-disc ratio 0.7 
or a difference in the vertical cup-to-disc ratio between the 
two eyes 0.2 was not detected before SLT treatment. In 
addition, a decrease in sensitivity in the visual fields on Hum-
phrey perimetric tests associated with ocular hypertension 
was also not present before the SLT treatment.
In three eyes, the mean ± standard deviation of the IOP 
before the SLT was 28.7 ± 2.1 mmHg, and the postopera-
tive mean IOP was 23.3 mmHg at one month, 28.0 mmHg 
at two months, 15.0 mmHg at three months, 15.3 mmHg at 
six months, and 13.3 mmHg at nine months. The percent-
age reduction in IOP was 21.6% ± 16.9%, 6.0% ± 7.2%, 
45.0% ± 26.9%, 48.0% ± 14.1%, and 52.7% ± 3.0% at the 
corresponding times. IOP in case 4 increased to 40 mmHg 
at four weeks after SLT and trabeculotomy (incision into 
Schlemm’s canal ab externo) was performed.7 In all cases, 
the ocular anti-hypertensive medications were discontinued 
after six months.
Discussion
SLT has been performed for open angle glaucoma, ocular 
hypertension, and steroid-induced glaucoma3,8 because it is 
less damaging to the trabecular meshwork.9 SLT was reported 
to reduce the mean IOP by 30% (7.7 ± 3.5 mmHg) for eyes 
with primary open-angle glaucoma.10 In our three eyes with 
a good response to SLT, IOP was reduced by 52.7% ± 3.0% 
at nine months, which was greater than that for eyes with 
primary open-angle glaucoma. SLT may be more effective 
for steroid-induced glaucoma after IVTA.3
It is possible that the disappearance of the drug from 
the subtenon space may have lowered the IOP. However, 
the typical increase in IOP response after IVTA has been 
reported to occur within one week in early cases but, in 
general, the increase in IOP peaks after a few months with 
a gradual decline to baseline between six to nine months 
after the injection.1,11–13 There are reports concluding that 
young age is a risk factor for elevated IOP after SITA and 
IVTA.1,4 Our findings suggested that SLT might lower the 
IOP from one month after SLT more effectively than the 
disappearance of the drug. In addition, SLT may be more 
effective for steroid-induced glaucoma as described for 
IVTA.3 However, we acknowledge that because of the lack 
of a treatment control group and the limited number of 
patients in the treatment group there exists the potential for 
misleading conclusions. Further investigations on a larger 
number of eyes are necessary to determine the efficacy of 
SLT by comparing the decrease with the natural decrease of 
IOP back to baseline.
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Table 1 Preoperative condition of patients
Case Age Gender Baseline IOP (mmHg) TA injection (mg) Preop IOP (mmHg) Preop medication
1 47 W 19 20 27 PG, beta, CAI
2 39 M 17 20 28 PG, beta, CAI, oral CAI
3 34 W 17 10 30 PG, beta, CAI
4 30 W 14 20 35 PG, beta, CAI, oral CAI
Abbreviations: F, woman; M, man; IOP, intraocular pressure; PG, latanoprost; beta, 2% hydrochloric carteolol; CAI, topical dorzolamide; oral CAI, systemic acetazolamide; TA, 
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Figure 1 Mean intraocular pressure (IOP) before and after SLT. The IOP decreases gradually in three eyes and one eye had a trabeculotomy (case 4).
Abbreviations: IOP, intraocular pressure; SLT, selective laser trabeculoplasty.